| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_5a9a7f9de230bf40ddd3f8db3b7f1fdf |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P3-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-502
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-55
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4418
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4453
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-495
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4545 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C13-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07C13-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D211-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D241-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-495
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-075
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-166 |
| filingDate |
2019-02-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_80d941672602053c8a25989d7fc80b01 |
| publicationDate |
2019-09-06-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-2019169082-A1 |
| titleOfInvention |
Methods of preventing and treating hypoglycemia in type 1 and type 2 diabetes patients |
| abstract |
Disclosed are methods for increasing glucagon secretion in response to exogenous insulin-induced hypoglycemia in patients with type l or type 2 diabetes. Also disclosed are methods of increasing glucagon secretion, and thus preventing or treating hypoglycemia, in patients with insulin producing tumors. The methods include administering a therapeutic amount of a histamine 1 receptor antagonist, a histamine 3 receptor antagonist, and/or a combination histamine 1/3 receptor antagonist. It may also be further advantageous to administer a therapeutic amount of a serotonin receptor antagonist in the methods disclosed herein. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-4053116-A4 |
| priorityDate |
2018-03-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |